SCHEMBL271073

SCHEMBL271073

CC(C)CCCNC=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8186479 0.95 ADH1B (0.54) —
SCHEMBL11354637 0.93 ADH1B (0.56) —
SCHEMBL11569625 0.93 ADH1B (0.56) —
SCHEMBL14937478 0.93 ADH1B (0.56) —
SCHEMBL11153834 0.93 ADH1B (0.56) —
SCHEMBL11568445 0.93 ADH1B (0.56) —
SCHEMBL269241 0.84 — —
SCHEMBL24607335 0.83 ADH1B (0.43) —
SCHEMBL278039 0.82 LMNA (0.52) —
SCHEMBL6756345 0.81 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 576 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111954532-A Anti-tumor multi-drug resistance of heteroaryl amide compounds, application of heteroaryl amide compounds in treating cancer and protein-drug molecular compound 上海交通大学医学院附属瑞金医院 2020-11-17 — — CN claimed
CN-111295387-A Heteroaryl amide compound, preparation method thereof, medicinal composition and application thereof 上海交通大学医学院附属瑞金医院 2020-06-16 — — CN claimed
CN-111170988-A Pyrazole formamide derivative containing substituted sulfimide acyl aryl, and preparation method and application thereof 南开大学 2020-05-19 — — CN claimed
WO-2019196111-A1 ANTI-TUMOR MULTIDRUG RESISTANCE OF HETEROARYL AMIDE COMPOUND, USE IN TREATMENT OF CANCERS AND PROTEIN-DRUG MOLECULAR COMPLEX 上海交通大学医学院附属瑞金医院 2019-10-17 — — WO claimed
US-20240226026-A1 BRANCHED TAIL LIPID COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS ARES CAPITAL CORPORATION, AS AGENT 2024-07-11 — — US disclosed
US-20240226026-A1 BRANCHED TAIL LIPID COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS ARES CAPITAL CORPORATION, AS AGENT 2024-07-11 — — US disclosed
CN-113226310-B 15-PGDH inhibitors 杏林制药株式会社 2024-03-19 — — CN disclosed
WO-2024043261-A1 AZO COMPOUND OR SALT THEREOF, AND POLARIZING FILM, POLARIZING PLATE AND LIQUID CRYSTAL DISPLAY DEVICE COMPRISING SAME 日本化薬株式会社 2024-02-29 — — WO disclosed
CN-114026199-B Polarized light emitting film, polarized light emitting panel and display device containing water-soluble coumarin compound or salt thereof 日本化药株式会社 2023-12-26 — — CN disclosed
US-11802208-B2 Stilbene-based compound or salt thereof, and polarizing film, polarizing plate, and display device NIPPON KAYAKU KABUSHIKI KAISHA (JP) 2023-10-31 — — US disclosed
WO-2023166975-A1 PEPTIDE COMPOUND PRODUCTION METHOD 国立大学法人徳島大学 2023-09-07 — — WO disclosed
US-20230127046-A1 G9a INHIBITOR RIKEN (JP) 2023-04-27 — — US disclosed
EP-0432893-A2 Benzoxazine derivatives, their preparation and pharmaceutical compositions containing them YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) 1991-06-19 — — EP disclosed
US-4987132-A PLATELET ACTIVATING FACTOR ANTAGONISTS YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) 1991-01-22 — — US disclosed
EP-0279681-A2 Saturated heterocyclic carboxamide derivatives YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) 1988-08-24 — — EP disclosed
US-4729992-A Cephalosporin esters, their production and use TATSUO CHEMICAL IND., LTD. (JP) 1988-03-08 — — US disclosed
US-4698339-A BETA-LACTAMASE INHIBITORS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1987-10-06 — — US disclosed
EP-0159899-A2 Cephalosporin esters, their production and use Takeda Chemical Industries, Ltd. (JP) 1985-10-30 — — EP disclosed
EP-0137403-A2 Carbapenems, their production and use Takeda Chemical Industries, Ltd. (JP) 1985-04-17 — — EP disclosed
US-3951965-A OPTICAL BRIGHTENERS HOECHST AKTIENGESELLSCHAFT (DT) 1976-04-20 — — US disclosed
Send feedback